Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and ...Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and safety profile of intravenous labetalol and hydralazine in the control hypertension in severe pre-eclampsia. Materials and Methods: One hundred patients who presented with severe pre-eclampsia were randomized into two study groups. The fifty patients in each arm of the study received either intravenous labetalol or intravenous hydralazine for the control of blood pressure. Results: The mean age of the labetalol subjects was 28.6 ± 5.47 years while that of their hydralazine counterparts was 29.12 ± 5.77 years. The majority of respondents in both groups were primigravidae (76% vs. 78%) (P = 0.813). The number of doses of drug needed to significantly lower the mean systolic blood pressure was slightly lower in the labetalol group (2 doses) compared to the hydralazine group (5 doses) (t = 0.803<sup>Y</sup>, P = 0.977). The incidence of headaches which were the commonest complaints was comparable in both groups 8% and 10% of respondents respectively (P > 0.05). Conclusion: Although both intravenous labetalol and hydralazine are useful in patients with severe pre-eclampsia, the response to labetalol was better with comparable side effects.展开更多
Objective: To explore the effect of Compound Danshen Injection combined with Labetalol on liver function and placental growth factor in patients with eclampsia. Methods: Seventy patients with eclampsia who were treate...Objective: To explore the effect of Compound Danshen Injection combined with Labetalol on liver function and placental growth factor in patients with eclampsia. Methods: Seventy patients with eclampsia who were treated in the Hospital from February 2017 to February 2019 were enrolled. The patients were divided into two groups according to the random number table, with 35 cases in each group. The Observation group was treated with Labetalol, and the combined therapy group was treated with Compound Danshen Injection combined with Labetalol. The liver function [alanine aminotransferase, aspartate aminotransferase, total protein, and albumin], hemorheology indicators, placental growth factor and serum insulin-like growth factor-1 and clinical indicators in the two groups were analyzed. Results: After treatment, the levels of alanine aminotransferase and aspartate aminotransferase in the combined therapy group were significantly lower than those in the Observation group. The levels of total protein and albumin in the combined therapy group were significantly higher than those in the Observation group (P<0.05). After treatment, the high-cut and low-cut whole blood viscosity, plasma viscosity and erythrocyte rigidity index in the combined therapy group were significantly lower than the Observation group, and the difference was statistically significant (P<0.05). After treatment, the levels of PLGF and IGF-1 in the combined therapy group were significantly higher than those in the Observation group, and the difference was statistically significant (P<0.05). After treatment, the gestational age, neonatal weight index, placental weight and neonatal 1 min Apgar score in the combined therapy group were significantly higher than the Observation group, and the difference was statistically significant (P<0.05). Conclusion: For patients with eclampsia, Compound Danshen Injection combined with Labetalol is with great safety, which can help stabilize their condition, and improve their liver function and placental growth factor status.展开更多
Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclam...Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclampsia. Methods: A total of 68 patients with severe preeclampsia who were treated in the hospital between October 2015 and August 2017 were chosen as the research subjects and divided into study group (n=34) and control group (n=34) by random number table method. Control group received magnesium sulfate therapy on the basis of conventional therapy, and study group received magnesium sulfate combined with labetalol therapy on the basis of conventional therapy. The differences in the expression of apoptosis and invasion molecules in placenta tissue as well as the levels of maternal endothelial function indexes were compared between the two groups. Results: Fas, Bax and Caspase-3 mRNA expression in the placenta tissues of study group were lower than those of control group whereas Bcl-2 mRNA expression was higher than that of control group;GPR30, LAMA4 and MEST mRNA expression in placenta tissues were lower than those of control group whereas CDKN1C mRNA expression was higher than that of control group;24 h before delivery, maternal serum ET-1 and vWF levels of study group were lower than those of control group whereas NO level was higher than that of control group (P<0.05). Conclusion: Magnesium sulfate combined with labetalol therapy can effectively inhibit the apoptosis of placental trophoblast cells and enhance their invasion ability, and also improve the maternal endothelial function in patients with severe preeclampsia.展开更多
目的分析拉贝洛尔联合硝苯地平对妊娠期高血压患者的临床治疗效果。方法110例妊娠期高血压患者,按治疗方法差异分为观察组(50例)和对照组(60例)。观察组使用拉贝洛尔联合硝苯地平治疗,对照组单用拉贝洛尔治疗。对比两组临床疗效、不良...目的分析拉贝洛尔联合硝苯地平对妊娠期高血压患者的临床治疗效果。方法110例妊娠期高血压患者,按治疗方法差异分为观察组(50例)和对照组(60例)。观察组使用拉贝洛尔联合硝苯地平治疗,对照组单用拉贝洛尔治疗。对比两组临床疗效、不良妊娠结局、血压[收缩压(SBP)、舒张压(DBP)]、尿蛋白指标[24 h尿蛋白定量(24 h U-Pro)]及C反应蛋白(CRP)和胎盘生长因子(PLGF)。结果观察组治疗总有效率为94.00%,明显高于对照组的76.67%(P<0.05)。观察组治疗后SBP(116.24±7.37)mm Hg(1 mm Hg=0.133 kPa)、DBP(81.63±6.16)mm Hg、24 h U-Pro(0.92±0.18)g/24 h均低于对照组的(134.05±9.21)mm Hg、(90.74±6.57)mm Hg、(1.75±0.27)g/24 h(P<0.05)。观察组治疗后CRP水平(8.15±1.33)mg/L明显低于对照组的(12.28±1.87)mg/L,PLGF水平(220.79±21.48)pg/ml明显高于对照组的(149.62±17.37)pg/ml(P<0.05)。观察组不良妊娠结局(胎儿宫内窘迫、新生儿窒息、胎盘早剥、羊水Ⅲ度浑浊、早产、产后出血)发生率18.00%明显低于对照组的45.00%(P<0.05)。结论拉贝洛尔联合硝苯地平对妊娠期高血压患者的临床治疗效果显著,能有效控制血压及蛋白尿,减轻炎症反应,保护胎盘功能,降低不良妊娠结局发生率。展开更多
文摘Objective: Intravenous labetalol and hydralazine are both considered first-line medications for the management of acute-onset, severe hypertension in pregnant and postpartum women. The study compared the efficacy and safety profile of intravenous labetalol and hydralazine in the control hypertension in severe pre-eclampsia. Materials and Methods: One hundred patients who presented with severe pre-eclampsia were randomized into two study groups. The fifty patients in each arm of the study received either intravenous labetalol or intravenous hydralazine for the control of blood pressure. Results: The mean age of the labetalol subjects was 28.6 ± 5.47 years while that of their hydralazine counterparts was 29.12 ± 5.77 years. The majority of respondents in both groups were primigravidae (76% vs. 78%) (P = 0.813). The number of doses of drug needed to significantly lower the mean systolic blood pressure was slightly lower in the labetalol group (2 doses) compared to the hydralazine group (5 doses) (t = 0.803<sup>Y</sup>, P = 0.977). The incidence of headaches which were the commonest complaints was comparable in both groups 8% and 10% of respondents respectively (P > 0.05). Conclusion: Although both intravenous labetalol and hydralazine are useful in patients with severe pre-eclampsia, the response to labetalol was better with comparable side effects.
基金2019 Provincial key research project of Hebei province (20191432)
文摘Objective: To explore the effect of Compound Danshen Injection combined with Labetalol on liver function and placental growth factor in patients with eclampsia. Methods: Seventy patients with eclampsia who were treated in the Hospital from February 2017 to February 2019 were enrolled. The patients were divided into two groups according to the random number table, with 35 cases in each group. The Observation group was treated with Labetalol, and the combined therapy group was treated with Compound Danshen Injection combined with Labetalol. The liver function [alanine aminotransferase, aspartate aminotransferase, total protein, and albumin], hemorheology indicators, placental growth factor and serum insulin-like growth factor-1 and clinical indicators in the two groups were analyzed. Results: After treatment, the levels of alanine aminotransferase and aspartate aminotransferase in the combined therapy group were significantly lower than those in the Observation group. The levels of total protein and albumin in the combined therapy group were significantly higher than those in the Observation group (P<0.05). After treatment, the high-cut and low-cut whole blood viscosity, plasma viscosity and erythrocyte rigidity index in the combined therapy group were significantly lower than the Observation group, and the difference was statistically significant (P<0.05). After treatment, the levels of PLGF and IGF-1 in the combined therapy group were significantly higher than those in the Observation group, and the difference was statistically significant (P<0.05). After treatment, the gestational age, neonatal weight index, placental weight and neonatal 1 min Apgar score in the combined therapy group were significantly higher than the Observation group, and the difference was statistically significant (P<0.05). Conclusion: For patients with eclampsia, Compound Danshen Injection combined with Labetalol is with great safety, which can help stabilize their condition, and improve their liver function and placental growth factor status.
文摘Objective: To investigate the effect of magnesium sulfate combined with labetalol on the apoptosis and invasion molecule expression in placenta as well as maternal endothelial function of patients with severe preeclampsia. Methods: A total of 68 patients with severe preeclampsia who were treated in the hospital between October 2015 and August 2017 were chosen as the research subjects and divided into study group (n=34) and control group (n=34) by random number table method. Control group received magnesium sulfate therapy on the basis of conventional therapy, and study group received magnesium sulfate combined with labetalol therapy on the basis of conventional therapy. The differences in the expression of apoptosis and invasion molecules in placenta tissue as well as the levels of maternal endothelial function indexes were compared between the two groups. Results: Fas, Bax and Caspase-3 mRNA expression in the placenta tissues of study group were lower than those of control group whereas Bcl-2 mRNA expression was higher than that of control group;GPR30, LAMA4 and MEST mRNA expression in placenta tissues were lower than those of control group whereas CDKN1C mRNA expression was higher than that of control group;24 h before delivery, maternal serum ET-1 and vWF levels of study group were lower than those of control group whereas NO level was higher than that of control group (P<0.05). Conclusion: Magnesium sulfate combined with labetalol therapy can effectively inhibit the apoptosis of placental trophoblast cells and enhance their invasion ability, and also improve the maternal endothelial function in patients with severe preeclampsia.
文摘目的分析拉贝洛尔联合硝苯地平对妊娠期高血压患者的临床治疗效果。方法110例妊娠期高血压患者,按治疗方法差异分为观察组(50例)和对照组(60例)。观察组使用拉贝洛尔联合硝苯地平治疗,对照组单用拉贝洛尔治疗。对比两组临床疗效、不良妊娠结局、血压[收缩压(SBP)、舒张压(DBP)]、尿蛋白指标[24 h尿蛋白定量(24 h U-Pro)]及C反应蛋白(CRP)和胎盘生长因子(PLGF)。结果观察组治疗总有效率为94.00%,明显高于对照组的76.67%(P<0.05)。观察组治疗后SBP(116.24±7.37)mm Hg(1 mm Hg=0.133 kPa)、DBP(81.63±6.16)mm Hg、24 h U-Pro(0.92±0.18)g/24 h均低于对照组的(134.05±9.21)mm Hg、(90.74±6.57)mm Hg、(1.75±0.27)g/24 h(P<0.05)。观察组治疗后CRP水平(8.15±1.33)mg/L明显低于对照组的(12.28±1.87)mg/L,PLGF水平(220.79±21.48)pg/ml明显高于对照组的(149.62±17.37)pg/ml(P<0.05)。观察组不良妊娠结局(胎儿宫内窘迫、新生儿窒息、胎盘早剥、羊水Ⅲ度浑浊、早产、产后出血)发生率18.00%明显低于对照组的45.00%(P<0.05)。结论拉贝洛尔联合硝苯地平对妊娠期高血压患者的临床治疗效果显著,能有效控制血压及蛋白尿,减轻炎症反应,保护胎盘功能,降低不良妊娠结局发生率。
